Intranasal administration of recombinant human interferon alfa-2b as prophylaxis of SARS-CoV-2 infection. (COVID-19)

Center for Genetic Engineering and Biotechnology (CIGB), in Havana0 个研究点目标入组 80 人开始时间: 2020年10月1日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention

•1) Virological diagnosis by RT-PCR of infection to SARS-CoV-2.
•2) Treatment with immunosuppressants in the last month prior to inclusion.
•3) Ongoing treatment, for any reason, with any IFN formulation.
•4) Acute illnesses in the last 30 days.
•5) Use of any other medication intranasally.
•6) Subjects who underwent tonsillectomy.
•7) History of allergic rhinitis and recurrent episodes of nasal bleeding.
•8) Active chronic asthma.
•9) Patients with myasthenia gravis.
•10) Chronic, autoimmune or endocrine-metabolic diseases decompensated at the time of inclusion.
•11) Administration of an investigational drug in the 30 days prior to inclusion in the study.
•12) Known hypersensitivity to thiomersal and any of the components of the formulation under study.
•13) Pregnancy or breastfeeding.
•14) Obvious mental incapacity to issue consent and act accordingly with the study.

发起方

Center for Genetic Engineering and Biotechnology (CIGB), in Havana